Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

 
Press Releases
  Date Title View
Sep 6, 2017
Mateon Therapeutics to Present at the 19th Annual Rodman and Renshaw Global Investment Conference on September 12, 2017

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference. Ma...

Aug 16, 2017
Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer

Primary Endpoint - Early Progression Free Survival data favors CA4PCA4P continues to be safe and well-toleratedNext interim analysis expected in September SOUTH SAN FRANCISCO, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatmen...

Aug 2, 2017
Mateon Provides Corporate Update and Reports Second Quarter 2017 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the three months ended June 30, 2017.  Recent Co...

Aug 1, 2017
Mateon Therapeutics Completes Enrollment in Phase 2 Portion of FOCUS Study of CA4P for Platinum-Resistant Ovarian Cancer

Recruitment rate significantly increased following initial positive interim analysisInterim data read-outs expected in August (40 patients), September (60 patients) and November (80 patients) SOUTH SAN FRANCISCO, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disr...

Jul 31, 2017
Mateon Therapeutics Announces Positive Initial Data from Fifth Cohort of Phase 1b Study of OXi4503 in Relapsed/Refractory AML

Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observed SOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced preliminary ...

Jun 28, 2017
Mateon Therapeutics Announces New Interim Preclinical Data on CA4P in Combination with Checkpoint Inhibitors

CA4P in combination with anti-CTLA-4 antibodies resulted in 77% reduction in tumor size compared to anti-CTLA-4 antibodies alone and 89% reduction compared to controlSurvival benefit observed for animals receiving combination therapy SOUTH SAN FRANCISCO, Calif., June 28, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharm...

Jun 12, 2017
Mateon Therapeutics Provides Update on its Clinical Trial Programs and Milestones

Interim Analyses for Key FOCUS Study Expected in August 2017 and September 2017Investigator-Sponsor Pauses Enrollment in PAZOFOS Study in U.K. SOUTH SAN FRANCISCO, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan...

Jun 7, 2017
Mateon Therapeutics Receives FDA Fast Track Designation for OXi4503 in Patients with Acute Myeloid Leukemia

SOUTH SAN FRANCISCO, Calif., June 07, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company's produ...

May 8, 2017
Mateon Provides Corporate Update and Reports First Quarter 2017 Financial Results

SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the three months ended March 31, 2017.  Recent Co...

Apr 27, 2017
Mateon Therapeutics Announces Presentations at the Tumor Microenvironment Workshop

SOUTH SAN FRANCISCO, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that four presentations regarding the company's preclinical drug development programs will be presented a...

1
...
NextLast
= add release to Briefcase